Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
ID: 355757Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $125K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355757

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-022.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at advancing research on RNA modifications and their implications in brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks innovative proposals that explore the molecular landscape of RNA modifications, focusing on their functional roles in AD and related disorders, with an emphasis on identifying biomarkers and therapeutic targets. The total funding available for fiscal year 2025 is $4 million, with up to six grants anticipated, each providing a maximum of $500,000 in direct costs per year over a five-year project period. Interested applicants can find more information and application guidelines at the NIH Grants website, and must submit their proposals by November 1, 2024, to be considered for this opportunity.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-022-Full-Announcement.html
    RFA-AG-25-022.html
    The National Institutes of Health (NIH) is launching a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at fostering research on the role of RNA modifications in brain aging and Alzheimer's disease (AD) and related dementias. This opportunity, under the R01 Research Project Grant mechanism, emphasizes the need for innovative studies elucidating the molecular landscape of RNA modifications, particularly their functional implications in AD and AD-related disorders. The funding, totaling $4 million for fiscal year 2025, anticipates awarding up to six grants, with a maximum budget of $500,000 in direct costs per year over a five-year project period. Eligible applicants include a wide range of institutions, including higher education establishments and nonprofit organizations. The announcement details application requirements, review criteria, and guidelines for submission via Grants.gov. Research proposals should explore various aspects of RNA modifications including identifying functional sites linked to AD, examining the machinery of RNA modification, and developing potential biomarkers for disease onset and progression. The initiative encourages collaboration and adherence to open-science principles, promoting rapid data sharing through the AD Knowledge Portal. This funding opportunity aligns with broader NIH goals of advancing understanding and therapeutic approaches for neurodegenerative diseases.
    Similar Opportunities
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative, aimed at advancing mechanistic research on RNA modifications that contribute to cancer development. This initiative seeks collaborative research projects that explore the role of mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation and progression, emphasizing the need for interdisciplinary expertise to address the complex interactions of these modifications. The estimated total program funding is $4.9 million, with an award ceiling of $650,000 for up to five projects, and the NOFO is expected to be published in early Fall 2024, with applications due in November 2024. Interested applicants are encouraged to prepare collaborations and can find additional information through the NCI Board of Scientific Advisors presentation linked in the opportunity overview.
    Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries," aimed at fostering collaborative research on Alzheimer's disease (AD) and related dementias (ADRD) in low- and middle-income countries (LMICs). This initiative seeks to build sustainable neuroscience research capacity by encouraging partnerships between U.S. researchers and scientists from LMICs, focusing on population-relevant studies that address the unique epidemiological and risk factors associated with AD/ADRD in diverse populations. The program will provide a total of $2.16 million for up to five awards, with individual application budgets capped at $400,000 annually over a five-year period. Interested applicants must submit their proposals by February 14, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.